Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A Systematic Approach to HIV-1 Vaccine Immunogen Selection.

Bontempo A, Garcia MM, Rivera N, Cayabyab MJ.

AIDS Res Hum Retroviruses. 2020 Feb 14. doi: 10.1089/AID.2019.0239. [Epub ahead of print]

PMID:
32056466
2.

Precision medicine: a call for increased pharmacogenomic education.

Ta R, Cayabyab MA, Coloso R.

Per Med. 2019 May 1;16(3):233-245. doi: 10.2217/pme-2018-0107. Epub 2019 Apr 26.

PMID:
31025601
3.

Correction: Oral Delivery of a Novel Recombinant Streptococcus mitis Vector Elicits Robust Vaccine Antigen-Specific Oral Mucosal and Systemic Antibody Responses and T Cell Tolerance.

Xie E, Kotha A, Biaco T, Sedani N, Zou J, Stashenko P, Duncan MJ, Campos-Neto A, Cayabyab MJ.

PLoS One. 2016 Jan 22;11(1):e0147781. doi: 10.1371/journal.pone.0147781. eCollection 2016. No abstract available.

4.

Oral Delivery of a Novel Recombinant Streptococcus mitis Vector Elicits Robust Vaccine Antigen-Specific Oral Mucosal and Systemic Antibody Responses and T Cell Tolerance.

Xie E, Kotha A, Biaco T, Sedani N, Zou J, Stashenko P, Duncan MJ, Campos-Neto A, Cayabyab MJ.

PLoS One. 2015 Nov 30;10(11):e0143422. doi: 10.1371/journal.pone.0143422. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0147781.

5.

Commensal Streptococcus mitis is a unique vector for oral mucosal vaccination.

Daifalla N, Cayabyab MJ, Xie E, Kim HB, Tzipori S, Stashenko P, Duncan M, Campos-Neto A.

Microbes Infect. 2015 Mar;17(3):237-42. doi: 10.1016/j.micinf.2014.11.002. Epub 2014 Dec 15.

6.

An unbiased peptide-wide discovery approach to select Mycobacterium tuberculosis antigens that target CD8+ T cell response during infection.

Cayabyab MJ, Qin L, Kashino SS, Izzo A, Campos-Neto A.

Vaccine. 2013 Oct 1;31(42):4834-40. doi: 10.1016/j.vaccine.2013.07.077. Epub 2013 Aug 9.

7.

Current and novel approaches to vaccine development against tuberculosis.

Cayabyab MJ, Macovei L, Campos-Neto A.

Front Cell Infect Microbiol. 2012 Dec 6;2:154. doi: 10.3389/fcimb.2012.00154. eCollection 2012. Review.

8.

Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol.

Cayabyab MJ, Kashino SS, Campos-Neto A.

Immunology. 2012 Mar;135(3):216-25. doi: 10.1111/j.1365-2567.2011.03525.x.

9.

Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.

Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, Carlson KR, Buzby AP, Haynes BF, Jacobs WR, Letvin NL.

J Virol. 2009 Jun;83(11):5505-13. doi: 10.1128/JVI.02544-08. Epub 2009 Mar 18.

10.

Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes.

Hovav AH, Panas MW, Rahman S, Sircar P, Gillard G, Cayabyab MJ, Letvin NL.

J Immunol. 2007 Nov 15;179(10):6725-33.

11.

The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells.

Hovav AH, Panas MW, Osuna CE, Cayabyab MJ, Autissier P, Letvin NL.

J Virol. 2007 Dec;81(23):12793-802. Epub 2007 Sep 19.

12.

Effects of type I interferons on the adjuvant properties of plasmid granulocyte-macrophage colony-stimulating factor in vivo.

Qin L, Greenland JR, Moriya C, Cayabyab MJ, Letvin NL.

J Virol. 2007 Oct;81(19):10606-13. Epub 2007 Jul 25.

13.

Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.

Hovav AH, Cayabyab MJ, Panas MW, Santra S, Greenland J, Geiben R, Haynes BF, Jacobs WR Jr, Letvin NL.

J Virol. 2007 Jan;81(1):74-83. Epub 2006 Oct 18.

14.

Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis.

Yu JS, Peacock JW, Vanleeuwen S, Hsu T, Jacobs WR Jr, Cayabyab MJ, Letvin NL, Frothingham R, Staats HF, Liao HX, Haynes BF.

Clin Vaccine Immunol. 2006 Nov;13(11):1204-11. Epub 2006 Aug 30.

15.

Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.

Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR, Lifton MA, Gorgone DA, Fennelly GJ, Haynes BF, Jacobs WR Jr, Letvin NL.

J Virol. 2006 Feb;80(4):1645-52.

16.

Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.

Song B, Cayabyab M, Phan N, Wang L, Axthelm MK, Letvin NL, Sodroski JG.

Virology. 2004 Apr 25;322(1):168-81.

17.

Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys.

Si Z, Gorry P, Babcock G, Owens CM, Cayabyab M, Phan N, Sodroski J.

AIDS Res Hum Retroviruses. 2004 Feb;20(2):163-73.

PMID:
15018704
18.

Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate.

Cayabyab M, Rohne D, Pollakis G, Mische C, Messele T, Abebe A, Etemad-Moghadam B, Yang P, Henson S, Axthelm M, Goudsmit J, Letvin NL, Sodroski J.

AIDS Res Hum Retroviruses. 2004 Jan;20(1):27-40.

PMID:
15000696
19.

Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.

Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D.

J Virol. 2002 Jun;76(12):6277-92.

20.

Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines.

Zhou N, Luo Z, Luo J, Fan X, Cayabyab M, Hiraoka M, Liu D, Han X, Pesavento J, Dong CZ, Wang Y, An J, Kaji H, Sodroski JG, Huang Z.

J Biol Chem. 2002 May 17;277(20):17476-85. Epub 2002 Mar 5.

22.

Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry.

Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J.

J Virol. 2000 Dec;74(24):11972-6.

23.

Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.

Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, Choe H, Sodroski J.

J Virol. 1999 Oct;73(10):8120-6.

24.

Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H.

Cell. 1999 Mar 5;96(5):667-76.

25.

Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2).

Cayabyab M, Karlsson GB, Etemad-Moghadam BA, Hofmann W, Steenbeke T, Halloran M, Fanton JW, Axthelm MK, Letvin NL, Sodroski JG.

J Virol. 1999 Feb;73(2):976-84.

26.

The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1.

Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, Cayabyab M, Berman M, Dorf ME, Gerard N, Gerard C, Sodroski J.

J Virol. 1998 Jul;72(7):6113-8.

27.

CD40 preferentially costimulates activation of CD4+ T lymphocytes.

Cayabyab M, Phillips JH, Lanier LL.

J Immunol. 1994 Feb 15;152(4):1523-31.

PMID:
7509825
28.

Requirements for CD28-dependent T cell-mediated cytotoxicity.

Azuma M, Cayabyab M, Phillips JH, Lanier LL.

J Immunol. 1993 Mar 15;150(6):2091-101.

PMID:
8383716
29.

Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line.

Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL.

J Immunol. 1992 Aug 15;149(4):1115-23.

PMID:
1380031
30.

Supplemental Content

Loading ...
Support Center